Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,872 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
Gangat N, Elbeih A, Ghosoun N, McCullough K, Aperna F, Johnson IM, Abdelmagid M, Al-Kali A, Alkhateeb HB, Begna KH, Elliott M, Mangaonkar A, Matin A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Yates S, Sneider A, Dworkin E, Patel AA, Bazinet A, Senapati J, Bataller A, DiNardo C, Kadia T, Tefferi A. Gangat N, et al. Among authors: shah m. Am J Hematol. 2024 Dec 13. doi: 10.1002/ajh.27564. Online ahead of print. Am J Hematol. 2024. PMID: 39671248
Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts.
Gangat N, McCullough K, Johnson I, Al-Kali A, Begna KH, Patnaik MM, Litzow MR, Hogan W, Shah M, Alkhateeb H, Mangaonkar A, Foran JM, Badar T, Palmer JM, Sproat L, Arana Yi CY, Pardanani A, Tefferi A. Gangat N, et al. Among authors: shah m. Am J Hematol. 2022 Jun 1;97(6):E214-E216. doi: 10.1002/ajh.26539. Epub 2022 Mar 24. Am J Hematol. 2022. PMID: 35303376 Free article. No abstract available.
Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.
Shah MV, Chhetri R, Dholakia R, Kok CH, Gangat N, Alkhateeb HB, Al-Kali A, Patnaik MM, Baranwal A, Greipp PT, He R, Begna KH, Tiong IS, Wei AH, Hiwase D. Shah MV, et al. Am J Hematol. 2022 Aug;97(8):1013-1022. doi: 10.1002/ajh.26589. Epub 2022 May 27. Am J Hematol. 2022. PMID: 35560061 Free PMC article.
A dynamic 3-factor survival model for acute myeloid leukemia that accounts for response to induction chemotherapy.
Tefferi A, Gangat N, Al-Kali A, Alkhateeb H, Shah M, Patnaik MS, Elliott MA, Hogan WJ, Litzow MR, Hook CC, Mangaonkar A, Viswanatha D, Chen D, Pardanani A, Ketterling RP, DiNardo CD, Kadia TM, Ravandi F, Sasaki K, Begna KH. Tefferi A, et al. Among authors: shah m. Am J Hematol. 2022 Sep;97(9):1127-1134. doi: 10.1002/ajh.26630. Epub 2022 Jun 30. Am J Hematol. 2022. PMID: 35702875 Free article.
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
Gangat N, Karrar O, Iftikhar M, McCullough K, Johnson IM, Abdelmagid M, Abdallah M, Al-Kali A, Alkhateeb HB, Begna KH, Mangaonkar A, Saliba AN, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A. Gangat N, et al. Among authors: shah m. Am J Hematol. 2024 Feb;99(2):193-202. doi: 10.1002/ajh.27138. Epub 2023 Dec 10. Am J Hematol. 2024. PMID: 38071734
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
Karrar O, Abdelmagid M, Rana M, Iftikhar M, McCullough K, Al-Kali A, Alkhateeb HB, Begna KH, Elliott MA, Mangaonkar A, Saliba A, Hefazi Torghabeh M, Litzow MR, Hogan W, Shah M, Patnaik MM, Pardanani A, Badar T, Murthy H, Foran J, Palmer J, Sproat L, Khera N, Arana Yi C, Tefferi A, Gangat N. Karrar O, et al. Among authors: shah m. Am J Hematol. 2024 Feb;99(2):E63-E66. doi: 10.1002/ajh.27180. Epub 2023 Dec 15. Am J Hematol. 2024. PMID: 38100217
Cardiac events in newly diagnosed acute myeloid leukaemia during treatment with venetoclax + hypomethylating agents.
Johnson IM, Karrar O, Rana M, Iftikhar M, Chen S, McCullough K, Saliba AN, Al-Kali A, Alkhateeb H, Begna K, Litzow M, Hogan WJ, Shah M, Patnaik MM, Pardanani A, Hermann J, Tefferi A, Gangat N. Johnson IM, et al. Among authors: shah m. Br J Haematol. 2024 Apr;204(4):1232-1237. doi: 10.1111/bjh.19325. Epub 2024 Feb 4. Br J Haematol. 2024. PMID: 38311378
The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS.
Alkharabsheh O, Al-Kali A, Saadeh S, He R, Viswanatha D, Greipp P, Reichard K, Shah M, Gangat N, Patnaik M, Hogan W, Litzow M, Alkhateeb H, Nguyen PL. Alkharabsheh O, et al. Among authors: shah m. Am J Hematol. 2018 Nov;93(11):E355-E357. doi: 10.1002/ajh.25239. Epub 2018 Oct 2. Am J Hematol. 2018. PMID: 30074268 Free article. No abstract available.
Elderly acute lymphoblastic leukemia: a Mayo Clinic study of 124 patients.
Miller KC, Al-Kali A, Shah MV, Hogan WJ, Elliott MA, Begna KH, Gangat N, Patnaik MM, Viswanatha DS, He R, Greipp PT, Sproat LZ, Foran JM, Litzow MR, Alkhateeb HB. Miller KC, et al. Among authors: shah mv. Leuk Lymphoma. 2019 Apr;60(4):990-999. doi: 10.1080/10428194.2018.1509318. Epub 2018 Oct 2. Leuk Lymphoma. 2019. PMID: 30277111
7,872 results